Company profile
Prime Medicine, Inc.
NASDAQ:PRMEBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06559176 | phase1_2 | enrolling_by_invitation | 2024-10-17 | 2030-01-01 | Prime Medicine, Inc. | A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD ) |
| NCT07748403 | phase1_2 | recruiting | 2026-09-01 | 2028-11-01 | Prime Medicine, Inc. | A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD) |
FDA applications (0)
No records yet.